Slingluff CL - Search Results

1

Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms.

Slingluff CL. Slingluff CL. Cancer Immunol Immunother. 1999 Oct;48(7):371-3. doi: 10.1007/s002620050588. Cancer Immunol Immunother. 1999. PMID: 10501849 Free PMC article. Review.

2

Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68.

Slingluff CL Jr, Cox AL, Stover JM Jr, Moore MM, Hunt DF, Engelhard VH. Slingluff CL Jr, et al. Cancer Res. 1994 May 15;54(10):2731-7. Cancer Res. 1994. PMID: 7513255

3

Direct analysis of tumor-associated peptide antigens.

Slingluff CL Jr, Hunt DF, Engelhard VH. Slingluff CL Jr, et al. Curr Opin Immunol. 1994 Oct;6(5):733-40. doi: 10.1016/0952-7915(94)90077-9. Curr Opin Immunol. 1994. PMID: 7530012 Review.

4

Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.

Slingluff CL Jr, Cox AL, Henderson RA, Hunt DF, Engelhard VH. Slingluff CL Jr, et al. J Immunol. 1993 Apr 1;150(7):2955-63. J Immunol. 1993. PMID: 7681084

5

Tumor antigens and tumor vaccines: peptides as immunogens.

Slingluff CL Jr. Slingluff CL Jr. Semin Surg Oncol. 1996 Nov-Dec;12(6):446-53. doi: 10.1002/(SICI)1098-2388(199611/12)12:6<446::AID-SSU10>3.0.CO;2-T. Semin Surg Oncol. 1996. PMID: 8914209 Review.

6

Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.

Skipper JC, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL Jr. Skipper JC, et al. Among authors: slingluff cl jr. J Immunol. 1996 Dec 1;157(11):5027-33. J Immunol. 1996. PMID: 8943411

7

Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.

Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr. Kittlesen DJ, et al. Among authors: slingluff cl jr. J Immunol. 1998 Mar 1;160(5):2099-106. J Immunol. 1998. PMID: 9498746

8

Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.

Harthun NL, Weaver AM, Brinckerhoff LH, Deacon DH, Gonias SL, Slingluff CL Jr. Harthun NL, et al. Among authors: slingluff cl jr. J Immunother. 1998 Mar;21(2):85-94. J Immunother. 1998. PMID: 9551359

9

The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene.

Hogan KT, Eisinger DP, Cupp SB 3rd, Lekstrom KJ, Deacon DD, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr, Ross MM. Hogan KT, et al. Among authors: slingluff cl jr. Cancer Res. 1998 Nov 15;58(22):5144-50. Cancer Res. 1998. PMID: 9823325

10

Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.

Skipper JC, Gulden PH, Hendrickson RC, Harthun N, Caldwell JA, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr. Skipper JC, et al. Among authors: slingluff cl jr. Int J Cancer. 1999 Aug 27;82(5):669-77. doi: 10.1002/(sici)1097-0215(19990827)82:5<669::aid-ijc9>3.0.co;2-#. Int J Cancer. 1999. PMID: 10417764

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

276 results

Search Page

Filters